Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rifampicin + clofazimine + dapsone
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
This drug is a fixed combination regimen of three antibiotics—rifampicin, clofazimine, and dapsone—used as the World Health Organization (WHO)-recommended multidrug therapy (MDT) for the treatment of all forms of leprosy. The combination is designed to prevent the development of drug resistance and to effectively cure both paucibacillary (PB) and multibacillary (MB) leprosy. Rifampicin acts as a potent bactericidal agent by inhibiting DNA-dependent RNA polymerase in Mycobacterium leprae. Clofazimine is a phenazine dye with antimycobacterial activity; it interferes with bacterial DNA function and also has anti-inflammatory properties. Dapsone is a sulfone antibiotic that inhibits folic acid synthesis in bacteria via antagonism of para-aminobenzoic acid (PABA). This regimen has been supplied free by WHO since 1995 to endemic countries[1][2][5][8].
- Other names
- multidrug therapy for leprosyMDT/WHO
02
Targets
NeuraminidaseRNAP (Bacterial dna-dependent RNA polymerase)DHPS (Dihydropteroate synthase)
Beyond the preview
Go deeper on rifampicin + clofazimine + dapsone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rifampicin + clofazimine + dapsone.